The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of immune checkpoint inhibitor dose on toxicity, response rate, and survival: A pooled analysis of dose escalation phase 1 trials.
 
Shiraj Sen
No Relationships to Disclose
 
Kenneth R. Hess
No Relationships to Disclose
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; Oncorena
Honoraria - Adaptimmune; Baxter; Bayer; Merrimack
Consulting or Advisory Role - Baxter; Bayer; Guidepoint Global; Janssen
Research Funding - Abbvie; Adaptimmune; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Genentech; Genmab; Ignyta; Infinity Pharmaceuticals; Kite, a Gilead company; Kyowa Hakko Kirin; Lilly; Loxo; MedImmune; Merck; Mirati Therapeutics; miRNA Therapeutics; Molecular Templates; Novartis; Pfizer; Takeda
Travel, Accommodations, Expenses - Loxo; miRNA Therapeutics
Other Relationship - Oncorena
 
Aung Naing
Consulting or Advisory Role - CytomX Therapeutics; Novartis
Research Funding - Amplimmune; ARMO BioSciences; Atterocor; Bristol-Myers Squibb; EMD Serono; Healios; Immune Cell Therapy (I); Incyte; Karyopharm Therapeutics; MedImmune; Merck; NCI; Novartis; Regeneron
Travel, Accommodations, Expenses - ARMO BioSciences
 
Le Huang
No Relationships to Disclose
 
Funda Meric-Bernstam
Honoraria - Dialectica; Sumitomo Group
Consulting or Advisory Role - Clearlight Diagnostics; DarwinHealth; Genentech; GRAIL; Inflection Biosciences; Pieris Pharmaceuticals; Samsung Bioepis
Research Funding - Abbvie; Aileron Therapeutics; AstraZeneca; Bayer; Calithera Biosciences; Curis; CytomX Therapeutics; Debiopharm Group; eFFECTOR Therapeutics; Genentech; Jounce Therapeutics; Novartis; Pfizer; PUMA Biotechnology; Taiho Pharmaceutical; Zymeworks
 
Vivek Subbiah
Consulting or Advisory Role - MedImmune
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; PharmaMar